ALLIANCES

9 Months Ended

Sep. 30, 2023

ALLIANCES [Abstract]

Alliances

ALLIANCES

BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS refers to these collaborations as alliances and its partners as alliance partners.

Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.

	Three Months Ended September 30,				Nine Months Ended September 30,
Dollars in millions	2023		2022		2023		2022
Revenues from alliances
Net product sales	$	2,762	$	2,722	$	9,614	$	9,234
Alliance revenues	138		173		461		560
Total alliance revenues	$	2,900	$	2,895	$	10,075	$	9,794
To/(from) alliance partners
Cost of products sold	$	1,330	$	1,328	$	4,650	$	4,456
Marketing, selling and administrative	(52)		(53)		(190)		(160)
Research and development	1		6		81		40
Acquired IPRD	—		—		55		100
Other (income)/expense, net	(10)		(18)		(37)		(41)

Dollars in millions	September 30, 2023		December 31, 2022
Selected alliance balance sheet information
Receivables – from alliance partners	$	209	$	317
Accounts payable – to alliance partners	1,288		1,249
Deferred income – from alliances(a)	289		289

(a) Includes unamortized upfront and milestone payments.

The nature, purpose, significant rights and obligations of the parties and specific accounting policy elections for each of the Company's significant alliances are discussed in the 2022 Form 10-K. Significant developments and updates related to alliances during the nine months ended September 30, 2023 and 2022 are set forth below.

BridgeBio

During the second quarter of 2022, BMS and BridgeBio commenced a collaboration to develop and commercialize BBP-398, a SHP2 inhibitor, in oncology. The transaction included an upfront payment of $90 million expensed to Acquired IPRD during the second quarter of 2022. BridgeBio is eligible to receive contingent development, regulatory and sales-based milestones up to $815 million, as well as royalties on global net sales, excluding certain markets. BridgeBio is responsible for funding and completing ongoing BBP-398 Phase I monotherapy and combination therapy trials. BMS is responsible for leading and funding all other development and commercial activities. BridgeBio has an option to co-develop BBP-398 and receive higher royalties in the U.S.